STOCK TITAN

SCYNEXIS (SCYX) 10-K Filings

SCYX NASDAQ

Here are the 10-K annual reports from SCYNEXIS, Inc. (SCYX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow SCYX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SCYX filings page.

Rhea-AI Summary

SCYNEXIS, Inc. focuses on severe fungal infections, built around its novel "fungerp" antifungal platform. Its first drug, ibrexafungerp (BREXAFEMME), is licensed globally to GSK for vulvovaginal candidiasis and recurrent VVC.

The lead wholly owned asset, SCY-247, completed single and multiple ascending dose Phase 1 oral studies in 88 healthy subjects, showing good tolerability and generally dose‑proportional pharmacokinetics. An intravenous Phase 1 trial began in early 2026, with a Phase 2 invasive candidiasis study planned for 2026.

Under a GSK license, SCYNEXIS ran the MARIO Phase 3 ibrexafungerp study, then agreed in an October 2025 memorandum to wind it down, receiving one‑time payments totaling $24.8 million in addition to a $10.0 million development milestone earlier in 2025.

SCYNEXIS reported an accumulated deficit of about $385.1 million and cash, cash equivalents and investments of $56.3 million as of December 31, 2025. The company expects continuing operating losses and will require substantial additional capital while it advances SCY‑247 and evaluates further partnering and in‑licensing opportunities.